Cargando…

Current Status of New Anticoagulants in the Management of Venous Thromboembolism

Venous Thromboembolism, manifested as deep venous thrombosis and pulmonary embolism, is a common problem associated with significant morbidity, mortality, and resource expenditure. Unfractionated heparin, low-molecular-weight heparin, and vitamin K antagonists are the most common treatment and proph...

Descripción completa

Detalles Bibliográficos
Autores principales: Montoya, Roberto C., Gajra, Ajeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310205/
https://www.ncbi.nlm.nih.gov/pubmed/22496694
http://dx.doi.org/10.1155/2012/856341
_version_ 1782227628231491584
author Montoya, Roberto C.
Gajra, Ajeet
author_facet Montoya, Roberto C.
Gajra, Ajeet
author_sort Montoya, Roberto C.
collection PubMed
description Venous Thromboembolism, manifested as deep venous thrombosis and pulmonary embolism, is a common problem associated with significant morbidity, mortality, and resource expenditure. Unfractionated heparin, low-molecular-weight heparin, and vitamin K antagonists are the most common treatment and prophylaxis, and have demonstrated their efficacy in a vast number of previous studies. Despite their broad use, these agents have important limitations that have led to the development of new drugs in a bid to overcome the disadvantages of the old ones without decreasing their therapeutic effect. These novel medications, some approved and others in different stages of development, include direct thrombin inhibitors like dabigatran etexilate, and direct activated factor X inhibitors like rivaroxaban. The current paper will review the characteristics, clinical trial results, and current and potential therapeutic uses of these new agents with a focus on the categories of direct thrombin inhibitors and activated factor X inhibitors.
format Online
Article
Text
id pubmed-3310205
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33102052012-04-11 Current Status of New Anticoagulants in the Management of Venous Thromboembolism Montoya, Roberto C. Gajra, Ajeet Adv Hematol Review Article Venous Thromboembolism, manifested as deep venous thrombosis and pulmonary embolism, is a common problem associated with significant morbidity, mortality, and resource expenditure. Unfractionated heparin, low-molecular-weight heparin, and vitamin K antagonists are the most common treatment and prophylaxis, and have demonstrated their efficacy in a vast number of previous studies. Despite their broad use, these agents have important limitations that have led to the development of new drugs in a bid to overcome the disadvantages of the old ones without decreasing their therapeutic effect. These novel medications, some approved and others in different stages of development, include direct thrombin inhibitors like dabigatran etexilate, and direct activated factor X inhibitors like rivaroxaban. The current paper will review the characteristics, clinical trial results, and current and potential therapeutic uses of these new agents with a focus on the categories of direct thrombin inhibitors and activated factor X inhibitors. Hindawi Publishing Corporation 2012 2012-03-08 /pmc/articles/PMC3310205/ /pubmed/22496694 http://dx.doi.org/10.1155/2012/856341 Text en Copyright © 2012 R. C. Montoya and A. Gajra. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Montoya, Roberto C.
Gajra, Ajeet
Current Status of New Anticoagulants in the Management of Venous Thromboembolism
title Current Status of New Anticoagulants in the Management of Venous Thromboembolism
title_full Current Status of New Anticoagulants in the Management of Venous Thromboembolism
title_fullStr Current Status of New Anticoagulants in the Management of Venous Thromboembolism
title_full_unstemmed Current Status of New Anticoagulants in the Management of Venous Thromboembolism
title_short Current Status of New Anticoagulants in the Management of Venous Thromboembolism
title_sort current status of new anticoagulants in the management of venous thromboembolism
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310205/
https://www.ncbi.nlm.nih.gov/pubmed/22496694
http://dx.doi.org/10.1155/2012/856341
work_keys_str_mv AT montoyarobertoc currentstatusofnewanticoagulantsinthemanagementofvenousthromboembolism
AT gajraajeet currentstatusofnewanticoagulantsinthemanagementofvenousthromboembolism